Special Issue Title:

Triple-Negative Breast Cancer: Focus on Diagnosis, Therapy, Prognosis

Deadline for manuscript submissions: 01 February 2023

Print Special Issue Flyer (5)

Special Issue Editor

  • Guest Editor

    Associate Prof. Guan WangE-MailWebsite

    West China Hospital, Sichuan University, China

    Interests: Breast Cancer; Targeted Small Molecule Drug; Drug Discovery; Pharmacology; Traditional Chinese Medicine; Medicinal Chemistry; Precision Nursing

  • Guest Editor

    Associate Prof. Lan ZhangE-MailWebsite

    School of Life Science and Engineering, Southwest Jiaotong University, China

    Interests: Breast Cancer; Targeted Small Molecule Drug; Drug Discovery; Drug Repurposing; Pharmacology; Medicinal Chemistry

  • Guest Editor

    Associate Prof. Jin ZhangE-MailWebsite

    School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, China

    Interests: Breast Cancer; Tumor Biological Target Identification; Oncology Pharmacology; Targeted Small Molecule Drug

Special Issue Information

Dear Colleagues,

As a special molecular subtype of breast cancer, Triple-Negative Breast Cancer (TNBC) refers to breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) amplification. Accounting for approximately 15% of breast cancer, TNBC has special molecular expression characteristics, biological behavior and clinicopathological characteristics, which manifested as relatively young onset, strong aggressiveness, high risk of early recurrence and high rate of distal metastasis. At present, conventional chemotherapy and radiotherapy and surgical excision are mostly used in the treatment of TNBC, but the therapeutic effect is still not satisfied with expectations. In recent years, with the deepening of basic research on TNBC, more and more targeted therapy and molecular mechanisms related to biotherapy have been revealed, such as the synthetic lethality of BRCA1/2 and PARP, PI3K/AKT/mTOR pathway, PD-1/PD-L1, etc. The continuous exploration of the pathogenesis of TNBC provides promising strategies and methods for the diagnosis, clinical treatment, nursing practice and prognosis of TNBC.

We accept manuscripts related to TNBC diagnosis, treatment, and prognosis. Equally important, we also invite researchers to share their recent discovery and validation of TNBC-related targets and related therapeutic entities, including traditional Chinese medicine and small molecule drugs.

Associate Prof. Guan Wang, Associate Prof. Lan Zhang and Associate Prof. Jin Zhang

Guest Editors


Triple-Negative Breast Cancer; Small Molecule Drug; Traditional Chinese Medicine; Epidemiological Investigation; Diagnosis; Therapy; Prognosis

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time